Document is current
Any future updates will be listed below
-
Authors
Poletti, Martina
Treveil, Agatha https://orcid.org/0000-0002-5600-8189
Csabai, Luca
Gul, Leila
Modos, Dezso
Madgwick, Matthew
Olbei, Marton
Bohar, Balazs
Valdeolivas, Alberto
Turei, Denes
Verstockt, Bram https://orcid.org/0000-0003-3898-7093
Triana, Sergio https://orcid.org/0000-0003-0370-7821
Alexandrov, Theodore https://orcid.org/0000-0001-9464-6125
Saez-Rodriguez, Julio https://orcid.org/0000-0002-8552-8976
Stanifer, Megan L. https://orcid.org/0000-0002-5606-1297
Boulant, Steeve
Korcsmaros, Tamas https://orcid.org/0000-0003-1717-996X
- License Information
-
More Information
Article History
Received: 5 November 2021
Accepted: 4 April 2022
First Online: 2 May 2022
Competing interests
: The Authors declare no Competing Non-Financial Interests but the following Competing Financial Interests: B. Verstockt reports financial support for research from Pfizer; lecture fees from Abbvie, Biogen, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda and Truvion; consultancy fees from Janssen, Guidepont and Sandoz, all outside of the submitted work; JSR received funding from GSK and Sanofi and consultant fees from Travere Therapeutics.
